Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMETRONIDAZOLE (metronidazole) by Ichnos Glenmark Innovation is clinical pharmacology normal subjects following a single, intravaginal 5 g dose of metronidazole vaginal gel (equivalent to 37. Approved for the treatment of bacterial vaginosis (formerly referred to, gardnerella vaginitis, nonspecific vaginitis and 2 more indications. First approved in 2022.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY Normal Subjects Following a single, intravaginal 5 g dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole) to 12 normal subjects, a mean maximum serum metronidazole concentration of 237 ng/mL was reported (range: 152 to 368 ng/mL). This is approximately 2%…
Worked on METRONIDAZOLE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Nitroimidazole Antimicrobial
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo